Multivariable network associated with cognitive decline and dementia

Neurobiology of Aging

Volumn 31, Issue 2, 2010, Pages 257-269

  Licastro, Federico ^a   Porcellini, Elisa ^a   Chiappelli, Martina ^a   Forti, Paola ^b   Buscema, Massimo ^c   Ravaglia, Giovanni ^b   Grossi, Enzo ^d  

^a Department of Experimental Pathology ^*  (Italy)

^b University School of Medicine   (Italy)

^c Semeion centro ricerche di scienze della communicazione   (Italy)

^d Bracco SpA   (Italy)

Author keywords

Brain aging; Connectivity map; Data base analysis; Dementia; Predictive factors

Indexed keywords

ALPHA 1 ANTICHYMOTRYPSIN; APOLIPOPROTEIN E; C REACTIVE PROTEIN; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 1BETA; INTERLEUKIN 6; NONSTEROID ANTIINFLAMMATORY AGENT; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR;

AGE; AGED; AGING; ARTICLE; CHOLESTEROL BLOOD LEVEL; COGNITIVE DEFECT; CONTROLLED STUDY; DATA MINING; DEMENTIA; FEMALE; FOLLOW UP; GENETIC ASSOCIATION; GENETIC VARIABILITY; HEREDITY; HUMAN; INFORMATION PROCESSING; INTERVIEW; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL ANALYSIS; MATHEMATICAL MODEL; MEDICAL EXAMINATION; PHENOTYPE; PRIORITY JOURNAL; PSYCHOLOGIC TEST; REFERENCE DATABASE;

AGED; AGING; BRAIN; CHOLESTEROL; COGNITION DISORDERS; DATA MINING; DATABASES AS TOPIC; DEMENTIA; FEMALE; FOLLOW-UP STUDIES; GENETIC VARIATION; HUMANS; HYDROXYMETHYLGLUTARYL COA REDUCTASES; INFORMATION THEORY; LONGITUDINAL STUDIES; MALE; MULTIVARIATE ANALYSIS; NONLINEAR DYNAMICS; PHENOTYPE;

EID: 71349084299     PISSN: 01974580     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2008.03.019     Document Type: Article

References (43)

1. Aronson M.K., Ooi W.L., Geva D.L., Masur D., Blau A., and Frishman W. Dementia. Age-dependent incidence, prevalence, and mortality in the old. Arch. Intern. Med. 151 5 (1991) 989-992
2. Bickeboller H., Campion D., Brice A., Amouyel P., Hannequin D., Didierjean O., Penet C., Martin C., Perez-Tur J., Michon A., Dubois B., Ledoze F., Thomas-Anterion C., Pasquier F., Puel M., Demonet J.F., Moreaud O., Babron M.C., Meulien D., Guez D., Chartier-Harlin M.C., Frebourg T., Agid Y., Martinez M., and Clerget-Darpoux F. Apolipoprotein E and Alzheimer disease: genotype-specific risks by age and sex. Am. J. Hum. Genet. 60 2 (1997) 439-446
3. Blennow K., de Leon M.J., and Zetterberg H. Alzheimer's disease. Lancet 368 (2006) 387-403
4. Buscema, M., Grossi, E. The Semantic Connectivity Map: an adapting self-organizing knowledge discovery method in data bases. Experience in Gastro-oesophageal reflux disease. Int. J. Data Mining Bioinform., in press.
5. Butte A.J., and Kohane I.S. Mutual information relevance networks: functional genomic clustering using pair-wise entropy measurements. Pac. Symp. Biocomput. (2000) 418-429
6. Chiappelli M., Borroni B., Archetti S., Calabrese E., Corsi M.M., Franceschi M., Padovani A., and Licastro F. VEGF gene and phenotype relation with Alzheimer's disease and mild cognitive impairment. Renjuvenation. Res. 9 4 (2006) 485-493
7. Chiappelli M., Tumini E., Porcellini E., and Licastro F. Impaired regulation of immune responses in cognitive decline and Alzheimer's diseases: lessons from genetic association study. Exp. Rev. Neurother. 6 (2006) 1327-1336
8. Cohen H.J., Harris T., and Pieper C.F. Coagulation and activation of inflammatory pathways in the development of functional decline and mortality in the elderly. Am. J. Med. 114 3 (2003) 180-187
9. Eto M., Watanabe K., and Ishii K. Reciprocal effects of apolipoprotein E alleles (epsilon 2 and epsilon 4) on plasma lipid levels in normolipidemic subjects. Clin. Genet. 29 6 (1986) 477-484
10. Forti P., Maioli F., Nesi B., Vettori C., Flisi E., Dalmonte E., Zanardi V., Lodi L., Macini P., Caldarera M., and Ravaglia G. Conselice study: a population based survey of brain aging in a municipality of the Emilia Romagna region: (A.U. S. L. Ravenna). Neuropsychological tests and nutritional status. Arch. Gerontol. Geriatr. Suppl. 7 (2001) 137-144
11. Frimmel H., Nappi J., and Yoshida H. Fast and robust computation of colon centerline in CT colonography. Med. Phys. 31 11 (2004) 3046-3056
12. Griffin W.S., Stanley L.C., Ling C., White L., MacLeod V., Perrot L.J., White III C.L., and Araoz C. Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc. Natl. Acad. Sci. USA 86 19 (1989) 7611-7615
13. Griffin W.S., Sheng J.G., Royston M.C., Gentleman S.M., McKenzie J.E., Graham D.I., Roberts G.W., and Mrak R.E. Glial-neuronal interactions in Alzheimer's disease: the potential role of a 'cytokine cycle' in disease progression. Brain Pathol. 8 1 (1998) 65-72
14. Grossi E., Buscema M.P., Snowdon D., and Antuono P. Neuropathological findings processed by artificial neural networks (ANNs) can perfectly distinguish Alzheimer's patients from controls in the Nun Study. BMC Neurol. 21 (2007) 7-15
15. Gruol D.L., and Nelson T.E. Physiological and pathological roles of interleukin-6 in the central nervous system. Mol. Neurobiol. 15 (1997) 307-339
16. Jick H., Zornberg G.L., Jick S.S., Seshadri S., and Drachmen D.A. Statins and the risk of dementia. Lancet 357 (2001) 562-565
17. Koudinov A.R., Berezov T.T., and Koudinova N. Alzheimer's amyloid beta and lipid metabolism: a missing link?. FASEB 12 (1998) 1097-1099
18. Kruskal J.B. On the shortest spanning subtree of a graph and the traveling-salesman problem. Proceedings of the American Mathematical Society 7 (1956) 48-50
19. Lahoz C., Schaefer E.J., Cupples L.A., Wilson P.W., Levy D., Osgood D., Parpos S., Pedro-Botet J., Daly J.A., and Ordovas J.M. Apolipoprotein E genotype and cardiovascular disease in the Framingham Heart Study. Atherosclerosis 154 3 (2001) 529-537
20. Lee U., Kim S., and Jung K.Y. Classification of epilepsy types through global network analysis of scalp electroencephalograms. Phys. Rev. E Stat. Nonlin. Soft. Matter Phys. 73 4 Pt 1 (2006) 041920
21. Li G., Larson E.B., Sonnen J.A., Shofer J.B., Petrie E.C., Schantz A., Peskind E.R., Raskind M.A., Breitner J.C.S., and Montine T.J. Statin therapy is associated with reduced neuropathologic changes of Alzheimer's disease. Neurology 69 (2007) 878-885
22. Licastro F., Campbell I.L., Kincaid C., Veinbergs I., Van Uden E., Rockenstein E., Mallory M., Gilbert J.R., and Masliah E. A role for apoE in regulating the levels of alpha-1-antichymotrypsin in the aging mouse brain and in Alzheimer's disease. Am. J. Pathol. 155 3 (1999) 869-875
23. Licastro F. Genomics of immune molecules: early detection of cognitive decline and new therapeuthic interventions. Expert Rev. Neurotherapeutics 2 5 (2002) 89-95
24. Licastro F., and Chiappelli M. Brain immune responses, cognitive decline and dementia relationship with phenotype expression and genetic background. Mech. Aging Develop. 124 (2003) 539-548
25. Licastro F., Chiappelli M., Grimaldi L.M.E., Morgan K., Kalsheker N., Calabrese E., Ritchie A., Porcellini E., Salani G., Franceschi M., and Canal N. A new promoter polymorphism in the alpha-1-antichymotrypsin gene is a disease modifier of Alzheimer's disease. Neurobiol. Aging 26 (2005) 449-453
26. Licastro F., Porcellini E., Caruso C., Lio D., and Corder E.H. Genetic risk profiles for Alzheimer's disease: integration of APOE genotype and variants that up-regulate inflammation. Neurobiol. Aging. 28 (2007) 1637-1643
27. Licastro, F., Porcellini, E., Davis, L.J., Chiappelli, M., Tumini, E., Forti, P., Ravaglia, G. Plasma α-1-antichymotrypsin age-related cognitive decline and Alzheimer's disease. JNNP, in press.
28. McGeer P.L., Kawamata T., Walzer D.G., Akiyama H., Tooyama I., and McGeer E.G. Microglia in degenerative neurological disease. Glia 7 (1993) 84-92
29. McKhann G., Drachman D., Folstein M., Katzman R., Price D., and Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34 7 (1984) 939-944
30. Mrak R.E., Sheng J.G., and Griffin W.S. Glial cytokines in Alzheimer's disease: review and pathogenic implications. Hum. Pathol. 26 8 (1995) 816-823
31. Porcellini E., Calabrese E., Guerini F., Govoni M., Chiappelli M., Tumini E., Morgan K., Chappell S., Kalsheker N., Franceschi M., and Licastro F. The hydroxy-methyl-glutaryl CoA reductase promoter polymorphism is associated with Alzheimer's risk and cognitive deterioration. Neurosci. Lett. 416 1 (2007) 66-70
32. Ravaglia G., Forti P., Maioli F., Orlanducci P., Sacchetti L., Flisi E., Dalmonte E., Martignani A., Cucinotta D., and Cavalli G. Conselice study: a population based survey of brain aging in a muncipality of the Emilia Romagna region: (A.U. S. L. Ravenna). Design and methods. Arch. Gerontol. Geriatr. Suppl. 7 (2001) 313-324
33. Ravaglia G., Forti P., Maioli F., Scali R.C., Arnone G., Talerico T., Pantieri T., Nativio V., Mantovani V., and Bianchin M. Common polymorphisms in methylentetrahydropholate reductase (MTHFR): relationship with plasma homocysteine concentrations and cognitive status in elderly northern Italian subjects. Arch. Gerontol. Geriat. Suppl. 9 (2004) 339-348
34. Ravaglia G., Forti P., Maioli F., Martelli M., Servadei L., Brunetti N., Porcellini E., and Licastro F. Homocysteine and folate as risk factors for dementia and Alzheimer disease. Am. J. Clin. Nutr. 82 (2005) 636-643
35. Ravaglia G., Forti P., Maioli F., Chiappelli M., Montesi F., Tumini E., Mariani E., Licastro F., and Patterson C. Blood inflammatory markers and risk of dementia: The Conselice Study of Brain Aging. Neurobiol. Aging. (2006, Sep. 28) p28
36. Ravaglia G., Forti P., Maioli F., Martelli M., Montesi F., Bastagli L., Bianchin M., Chiappelli M., Tumini E., Bolondi L., and Licastro F. Interleukin-1beta and interleukin-6 gene polymorphisms as risk factors for AD: a prospective study. Exper. Gerontol. 41 (2006) 85-92
37. Ravaglia G., Forti P., Maioli F., Montesi F., Rietti E., Pisacane N., Rolfo E., Scali C.R., and Dal monte E. Risk factors for dementia: data from The Conselice Study of brain aging. Arch. Gerontol. Geriatr. Suppl. 1 (2007) 311-320
38. Rea T.D., Breitner J.C., Psaty B.M., Fitzpatrick A.L., Lopez O.L., Newman A.B., Hazzard W.R., Zandi P.P., Burke G.L., Lyketsos C.G., Bernick C., and Kuller L.H. Statin use and the risk of incident dementia: the cardiovascular health study. Arch. Neurol. 62 (2005) 1047-1051
39. Rogers J., Luber-Narod J., Styren S.D., and Civin W.H. Expression of immune system-associated antigens by cells of the human central nervous system: relationship to the pathology of Alzheimer's disease. Neurobiol. Aging 9 (1988) 339-349
40. Roman G.C., Tatemichi T.K., Erkinjuntti T., Cummings J.L., Masdeu J.C., Garcia J.H., Amaducci FL., Orgogozo J.M., Brun A., Hofman A., et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 43 2 (1993) 250-260
41. Terry R.D. Neuropathological changes in Alzheimer's disease. Prog. Brain Res. 101 (1994) 383-390
42. Trojanowski J.Q., Clark C.M., Schmidt M.L., Arnold S.E., and Lee V.M. Strategies for improving the postmortem neuropathological diagnosis of Alzheimer's disease. Neurobiol. Aging 18 4 Suppl. (1997) S75-S79
43. Zhang F.L., and Casey P.J. Protein prenylation: molecular mechanisms and functional consequences. Annu. Rev. Biochem. 65 (1996) 241-269